Low-dose targeted radiation alone for marginal zone lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests whether very low-dose radiation (adjusted based on how you respond) can treat marginal zone lymphoma without adding other medicines at first. It may help some people by reducing radiation exposure while still controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older).
- Your lymphoma must be stage I or II marginal zone lymphoma confirmed by pathology.
- After radiation starts, you cannot be planned for chemotherapy or other whole-body medicines until after the first follow-up check.
- If you had treatment before radiation (like pills or other procedures), there must be evidence of remaining disease on scan, exam, or endoscopy before joining.
- You cannot be pregnant, and you must use reliable birth control during radiation and for a set time afterward (details depend on your situation).
- You must be able to follow the study plan and sign consent; severe mental health or social issues that prevent follow-up can exclude you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a reduced dose of radiation therapy works well for certain types of B-cell lymphomas, specifically follicular lymphoma and marginal zone lymphoma. It aims to minimize side effects while still controlling the disease.
This study tests whether adding low-dose radiation to standard chemoimmunotherapy can improve outcomes for people with newly diagnosed large B-cell lymphoma, using a personalized blood test to guide who gets radiation. It may help reduce the risk of the lymphoma returning by targeting sites still showing signs of disease.
This study tests a combination of a low dose of radiation and an oral targeted drug (orelabrutinib) for people with early-stage MALT lymphoma. The goal is to see if adjusting the treatment based on your response can be effective and reduce side effects.
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
This trial tests a new combination of two drugs for people with a type of lymphoma called marginal zone lymphoma who have not had prior systemic treatment. It aims to see if the combination can shrink or control the cancer and improve quality of life.
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.